Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antifungal agents.

N S Ryder1

  • 1Novartis Research Institute, Brunner Strasse 59, A-1235 Vienna, Austria. neil.ryder@pharma.Novartis.com

Idrugs : the Investigational Drugs Journal
|August 23, 2005
PubMed
Summary
This summary is machine-generated.

New antifungal agents are in development, including triazoles and echinocandins. A key finding is the emergence of efflux pump inhibitors to combat antifungal resistance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Activity of terbinafine against serious fungal pathogens.

Mycoses·2017
Same author

Nonspecific effect of Mycograb on amphotericin B MIC.

Antimicrobial agents and chemotherapy·2012
Same author

A collaborative hit-to-lead investigation leveraging medicinal chemistry expertise with high throughput library design, synthesis and purification capabilities.

Combinatorial chemistry & high throughput screening·2006
Same author

Antifungal drug response in an in vitro model of dermatophyte nail infection.

Medical mycology·2004
Same author

Alpha-substituted hydroxamic acids as novel bacterial deformylase inhibitor-based antibacterial agents.

Bioorganic & medicinal chemistry letters·2003
Same author

In vitro susceptibility of Microsporum canis and other dermatophyte isolates from veterinary infections during therapy with terbinafine or griseofulvin.

Medical mycology·2002
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • The 20th International Congress of Chemotherapy and Infection (ICAAC) Meeting featured updates on approximately 20 antifungal agents.
  • While no entirely new antifungal agents were disclosed, several compounds are in late-stage development.

Purpose of the Study:

  • To summarize new data and emerging strategies in antifungal drug development presented at the ICAAC Meeting.
  • To highlight advancements in combating antifungal resistance through novel mechanisms.

Main Methods:

  • Review of presentations on antifungal agents at the ICAAC Meeting.
  • Analysis of clinical trial data for novel antifungal compounds and resistance-modulating strategies.

Main Results:

Related Experiment Videos

  • Late-stage development includes triazoles (voriconazole, Sch-56592) and echinocandins (caspofungin, FK-463).
  • Early clinical results for FK-463 showed tolerability and efficacy in AIDS-associated esophageal candidiasis.
  • Liposomal nystatin (Nyotran) demonstrated equivalence to amphotericin B with reduced toxicity.
  • Intravenous itraconazole showed prophylactic efficacy against invasive pulmonary aspergillosis.
  • Terbinafine exhibited efficacy against fungal mycetoma.
  • First presentation of fungal efflux pump inhibitors (e.g., MC-510027, MC-005172) potentiated existing antifungals against Candida spp. and in vivo models.

Conclusions:

  • Antifungal drug development continues with promising agents in late-stage trials.
  • Inhibitors of fungal efflux pumps represent a significant new strategy to overcome antifungal resistance.